
Morgan Stanley analyst Matthew Harrison raised the firm’s price target on Atea Pharmaceuticals (AVIR) to $8 from $7 and keeps an Equal Weight rating on the shares. Published first on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals | 3.96 | 0.97 | 32.32% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.96 | +32.32% |

Morgan Stanley analyst Matthew Harrison raised the firm’s price target on Atea Pharmaceuticals (AVIR) to $8 from $7 and keeps an Equal Weight rating on the shares. Published first on

Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q3 earnings call. Read on for the main highlights of the call. Atea Pharmaceuticals’ earnings call carried a largely positive tone, led by

The latest update is out from Atea Pharmaceuticals ( ($AVIR) ). On November 6, 2026, Atea Pharmaceuticals entered into a loan and security agreement with Hercules Capital as agent and

Atea Pharmaceuticals, Inc. (AVIR) is scheduled to report 3rd quarter earnings on 11/09/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Atea Pharmaceuticals, Inc. to post earnings

Atea Pharmaceuticals, Inc. ($AVIR) announced an update on their ongoing clinical study. Atea Pharmaceuticals, Inc. is running a Phase 3 study called C-BEYOND to compare its new hepatitis C pill

Atea Pharmaceuticals, Inc. ($AVIR) announced an update on their ongoing clinical study. Atea Pharmaceuticals, Inc. is running a Phase 1 study called “A Phase 1, Open-Label, Two-Part, Single-Sequence Study to

Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q2 earnings call. Read on for the main highlights of the call. Atea Pharmaceuticals’ latest earnings call struck a cautiously upbeat tone as

Morgan Stanley raised the firm’s price target on Atea Pharmaceuticals (AVIR) to $7 from $6 and keeps an Equal Weight rating on the shares. Published first on TheFly – the

Atea Pharmaceuticals, Inc. (AVIR) is scheduled to report 2nd quarter earnings on 08/12/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Atea Pharmaceuticals, Inc. to post earnings

Atea Pharmaceuticals, Inc. ($AVIR) announced an update on their ongoing clinical study. Atea Pharmaceuticals, Inc. (AVIR) has completed a Phase 1 study called “Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $315.60M | $-0.44 | $0.00 | 0.61 | -2.02 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.